The White House Just Told the FDA to Fast-Track Psychedelics

The Compass Pathways Connection

If one company stands to benefit more than any other, it's Compass Pathways. The British biotech has been developing COMP360, a synthetic, pharmaceutical-grade psilocybin (the active ingredient in magic mushrooms) for treatment-resistant depression. Patients receive a single 25 mg dose during a supervised six-to-eight-hour session with psychological support.

The clinical data has been strong. Both of Compass's Phase 3 trials (COMP005 and COMP006) hit their primary endpoints, which is science-speak for "the drug did what it was supposed to do." Across more than 1,000 participants in the Phase 2b and Phase 3 trials combined, effects showed up within a single day and lasted at least six months for patients who responded. Over 40% of patients who didn't fully recover after one dose achieved remission after a second.

Compass already had FDA Breakthrough Therapy designation, granted back in 2018. But on April 24, just six days after the executive order, the FDA handed Compass a Commissioner's National Priority Voucher. The company plans to complete its rolling NDA (new drug application) submission by Q4 2026, and with the priority voucher accelerating review to roughly one to two months post-filing, an FDA decision could come as early as Q1 2027.

To put that in perspective: without the voucher, a standard priority review would push the decision to mid-2027 at the earliest. The executive order essentially moved the finish line closer by several months.

Compass also raised roughly $350 million in February 2026, giving it runway through 2028. Translation: they have enough cash to cross the finish line without needing to pass the hat again.

The Ghost of MDMA Past

Not everyone in the psychedelic space is popping champagne. The industry still carries bruises from August 2024, when the FDA rejected Lykos Therapeutics' MDMA therapy for PTSD. That decision stung. Lykos had Breakthrough Therapy designation and promising Phase 3 data. But the FDA wanted another Phase 3 study, citing concerns about efficacy evidence and safety.

That rejection was like watching a student ace the SAT but get told to retake it anyway. It spooked investors and cast a shadow over the entire sector. The Ninth Circuit made things worse in 2025 by ruling against psilocybin access under the Right to Try Act.

The executive order directly addresses both of those pain points. It expands Right to Try eligibility for psychedelics and signals that the FDA should lean toward approval, not caution, for drugs with strong evidence. Whether the FDA actually changes its behavior remains to be seen; the agency retains significant discretion regardless of what any executive order says.

The Bigger Chessboard

Compass isn't playing alone. The psychedelic medicine landscape now includes dozens of companies at various stages of development.

AtaiBeckley (formed from the merger of ATAI Life Sciences and Beckley Psytech) completed Phase 2b for its nasal spray treatment for treatment-resistant depression and is planning Phase 3 trials. Definium Therapeutics, formerly MindMed, is running Phase 3 trials on an LSD derivative for major depression and anxiety. The DEA raised its 2026 psilocybin production quota by 67%, a quieter but telling sign that the federal government is making room for this industry to grow.

Legal and policy experts have taken notice. Harvard's I. Glenn Cohen called the order a "significant signal" for accelerated review and reduced research barriers. The consensus among analysts: the order de-risks late-stage trials and could encourage a wave of private investment, even if the $50 million in federal funding is relatively modest.

So, Will This Actually Change Anything?

Executive orders are powerful, but they're not magic wands. The FDA still has to follow its evidence standards. The DEA still controls scheduling. And reimbursement (who pays for a six-hour supervised psilocybin session?) remains completely unaddressed.

But the signal matters enormously. Two years ago, psychedelic medicine felt like it was stuck in regulatory purgatory: promising science, hostile bureaucracy. Now the White House is publicly telling agencies to get out of the way. The DEA is boosting production quotas. And the closest-to-market psychedelic drug just got a golden ticket to the front of the FDA's review queue.

The psychedelic medicine industry has been waiting years for a moment like this. Whether the moment delivers real change, or just good headlines, depends on what happens over the next twelve months. Compass Pathways' NDA filing later this year will be the first real test. If COMP360 gets approved, it won't just be the first psilocybin drug on the U.S. market. It'll be proof that Washington and psychedelics can actually get along.